BSA-conjugated mannan derived from C. albicans cell wall

The dose-dependent efficacy of mannan-BSA in protecting mice from invasive aspergillosis appears to reside in the 500 kDa and not the 40 kDa fraction, and this finding will affect further vaccine development. Higher doses of mannan-BSA 40 kDa may be needed to show efficacy. Study of the immune response and epitope mapping would help to understand the mechanism underlying mannan-induced protection.